CRIS Current Research Information System

MARZOCCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.880
AS - Asia 2.791
EU - Europa 2.103
AF - Africa 190
SA - Sud America 127
OC - Oceania 3
Totale 8.094
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.847
VN - Vietnam 951
CN - Cina 701
SG - Singapore 675
GB - Regno Unito 454
IT - Italia 438
SE - Svezia 317
DE - Germania 256
HK - Hong Kong 165
IN - India 125
NL - Olanda 110
RU - Federazione Russa 101
FR - Francia 94
BR - Brasile 92
KR - Corea 75
IE - Irlanda 74
UA - Ucraina 61
CI - Costa d'Avorio 57
FI - Finlandia 46
ZA - Sudafrica 39
SC - Seychelles 38
TG - Togo 38
EE - Estonia 33
BG - Bulgaria 30
CH - Svizzera 29
JO - Giordania 27
JP - Giappone 23
CA - Canada 22
AR - Argentina 18
BE - Belgio 18
NG - Nigeria 13
AT - Austria 10
IR - Iran 10
MX - Messico 10
GR - Grecia 7
BD - Bangladesh 6
CL - Cile 6
ID - Indonesia 6
PH - Filippine 6
PL - Polonia 6
CZ - Repubblica Ceca 5
TR - Turchia 5
ES - Italia 4
SA - Arabia Saudita 4
EC - Ecuador 3
PY - Paraguay 3
CO - Colombia 2
IL - Israele 2
IQ - Iraq 2
MY - Malesia 2
NO - Norvegia 2
RS - Serbia 2
AU - Australia 1
BO - Bolivia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GM - Gambi 1
HU - Ungheria 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
NC - Nuova Caledonia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
YT - Mayotte 1
Totale 8.094
Salva come PNG Salva come JPEG
Città #
Singapore 464
Southend 394
Ashburn 344
Chandler 312
Fairfield 274
Dong Ket 207
Ho Chi Minh City 191
Hefei 166
Hong Kong 164
Woodbridge 152
Seattle 135
Hanoi 126
Wilmington 126
Houston 122
Ann Arbor 116
Cambridge 116
Beijing 103
Bologna 103
Princeton 87
Dallas 84
Dublin 74
Seoul 74
Boardman 65
Santa Clara 62
Abidjan 57
New York 52
Turin 41
Helsinki 40
Lomé 38
Nanjing 37
Westminster 35
Padova 34
Bremen 33
Milan 31
Los Angeles 30
Sofia 30
Jacksonville 29
Berlin 28
Amman 27
Florence 27
Haiphong 25
Jinan 25
Munich 24
Bern 22
Hyderabad 22
Tokyo 20
Redondo Beach 19
Saint Petersburg 19
Brussels 18
San Diego 18
Shenyang 18
Bengaluru 16
Buffalo 16
Frankfurt am Main 16
Redmond 16
Tianjin 14
Biên Hòa 13
Ha Long 13
Nanchang 13
São Paulo 13
Abeokuta 12
Guangzhou 12
Hebei 12
Redwood City 12
Zhengzhou 12
Brooklyn 10
Castelfranco Emilia 10
Fabriano 10
Falkenstein 10
Falls Church 10
Quận Bình Thạnh 10
Toronto 10
Da Nang 9
Hangzhou 9
Nuremberg 9
Quận Một 9
Thái Nguyên 9
Casalecchio di Reno 8
Des Moines 8
Düsseldorf 8
Lauterbourg 8
Paris 8
Taizhou 8
Atlanta 7
Changsha 7
Chengdu 7
London 7
Medford 7
Ninh Bình 7
Phoenix 7
San Francisco 7
Tongling 7
Washington 7
Amsterdam 6
Andover 6
Bắc Ninh 6
Denver 6
Mülheim 6
Orem 6
Quận Phú Nhuận 6
Totale 5.325
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 664
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 317
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 285
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 231
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 230
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 207
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 200
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 195
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 192
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 184
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 183
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 181
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 176
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 172
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 169
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 169
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 169
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 165
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 163
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 155
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 153
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 153
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 152
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 151
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 151
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 148
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 138
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 137
Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. 135
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 134
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 133
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 131
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 131
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 131
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 129
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 120
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 109
null 104
null 102
null 98
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 96
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 91
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 87
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 87
Proteasome inhibitors: Bortezomib in multiple myeloma 76
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 52
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 51
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 32
Totale 8.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021570 0 0 0 0 0 0 15 43 63 19 49 381
2021/20221.044 141 41 54 107 79 43 23 61 41 121 167 166
2022/20231.215 120 193 66 170 67 97 39 69 195 38 115 46
2023/2024394 24 42 23 40 39 106 16 35 6 18 28 17
2024/20251.197 65 108 91 101 150 54 106 43 16 176 76 211
2025/20262.054 325 755 281 223 310 148 12 0 0 0 0 0
Totale 8.223